EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 101-110

  Zhu, Hu ^a   Cao, Xinyu ^a   Ali Osman, Francis ^a,b   Keir, Stephen ^a,b  

^a   (United States)

^b   (United States)

Author keywords

Apoptosis; Chemoresistance; EGFR; EGFRvIII; Glioblastoma; PUMA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PROTEIN BCL 2; PROTEIN P53; PUMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CELL STRESS; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASTROCYTOMA; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA TRANSPOSABLE ELEMENTS; FEMALE; GENETIC VARIATION; GLIOBLASTOMA; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953017646     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.028     Document Type: Article

References (55)

1. James C.D., Cavenee W.K. Stem cells for treating glioblastoma: how close to reality?. Neuro Oncol. 2009, 11(2):101.
2. Wong A.J., Bigner S.H., Bigner D.D., Kinzler K.W., Hamilton S.R., Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl.Acad. Sci. USA 1987, 84(19):6899-6903.
3. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87(21):8602-8606.
4. Hodgson J.G., Yeh R.F., Ray A., Wang N.J., Smirnov I., Yu M., Hariono S., Silber J., Feiler H.S., Gray J.W., Spellman P.T., Vandenberg S.R., Berger M.S., James C.D. Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts. Neuro Oncol. 2009.
5. Yamazaki H., Ohba Y., Tamaoki N., Shibuya M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn. J. Cancer Res. 1990, 81(8):773-779.
6. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89(7):2965-2969.
7. Lo H.W., Hung M.C. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression nitric oxide pathway and patient survival. Brit. J. Cancer 2006, 94(2):184-188.
8. Lautrette A., Li S., Alili R., Sunnarborg S.W., Burtin M., Lee D.C., Friedlander G., Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 2005, 11(8):867-874.
9. Lo H.W., Cao X., Zhu H., Ali-Osman F. Constitutively activated STAT3 Frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and Alkylators. Clin. Cancer Res. 2008, 14(19):6042-6054.
10. Yang Z., Bagheri-Yarmand R., Wang R.A., Adam L., Papadimitrakopoulou V.V., Clayman G.L., El-Naggar A., Lotan R., Barnes C.J., Hong W.K., Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin. Cancer Res. 2004, 10(2):658-667.
11. Lo H.-W. EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr. Mol. Pharmacol. 2010, 3(1).
12. Omuro A.M.P., Faivre S., Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 2007, 6(7):1909-1919.
13. Reardon D.A., Quinn J.A., Vredenburgh J.J., Gururangan S., Friedman A.H., Desjardins A., Sathornsumetee S., Herndon J.E., Dowell J.M., McLendon R.E., Provenzale J.M., Sampson J.H., Smith R.P., Swaisland A.J., Ochs J.S., Lyons P., Tourt-Uhlig S., Bigner D.D., Friedman H.S., Rich J.N. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 2006, 12(3 Pt. 1):860-868.
14. Friedman H.S., Bigner D.D. Glioblastoma multiforme and the epidermal growth factor receptor. New Engl. J. Med. 2005, 353(19):1997-1999.
15. de Groot J.F., Gilbert M.R., Aldape K., Hess K.R., Hanna T.A., Ictech S., Groves M.D., Conrad C., Colman H., Puduvalli V.K., Levin V., Yung W.K. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neuro Oncol. 2008, 90(1):89-97.
16. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 2005, 352(8):786-792.
17. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
18. Marie Y., Carpentier A.F., Omuro A.M., Sanson M., Thillet J., Hoang-Xuan K., Delattre J.Y. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 2005, 64(8):1444-1445.
19. Willis S.N., Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 2005, 17(6):617-625.
20. Cotter T.G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. 2009, 9(7):501-507.
21. Danial N.N. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res. 2007, 13(24):7254-7263.
22. Gelinas C., White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Devel. 2005, 19(11):1263-1268.
23. Vogelbaum M.A., Tong J.X., Perugu R., Gutmann D.H., Rich K.M. Overexpression of bax in human glioma cell lines. J. Neurosurg. 1999, 91(3):483-489.
24. Sun Q., Ming L., Thomas S.M., Wang Y., Chen Z.G., Ferris R.L., Grandis J.R., Zhang L., Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009, 28(24):2348-2357.
25. Naresh A., Long W., Vidal G.A., Wimley W.C., Marrero L., Sartor C.I., Tovey S., Cooke T.G., Bartlett J.M.S., Jones F.E. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 2006, 66(12):6412-6420.
26. McFarland B.C., Stewart J., Hamza A., Nordal R., Davidson D.J., Henkin J., Gladson C.L. Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1. Cancer Res. 2009, 69(13):5537-5545.
27. George J., Gondi C.S., Dinh D.H., Gujrati M., Rao J.S. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin. Cancer Res. 2007, 13(12):3507-3517.
28. Ali-Osman F., Stein D.E., Renwick A. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. Cancer Res. 1990, 50(21):6976-6980.
29. Lo H.W., Zhu H., Cao X., Aldrich A., Ali-Osman F. A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Res. 2009, 69(17):6790-6798.
30. Camp R.L., Rimm E.B., Rimm D.L. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86(11):2259-2265.
31. Lo H.-W., Hsu S.-C., Xia W., Cao X., Shih J.-Y., Wei Y., Abbruzzese J.L., Hortobagyi G.N., Hung M.-C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007, 67(19):9066-9076.
32. Lo H.W., Stephenson L., Cao X., Milas M., Pollock R., Ali-Osman F. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol. Cancer Res. 2008, 6(5):843-850.
33. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
34. Lo H.-W., Hsu S.-C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.-Y., Hung M.-C. Nuclear interaction of EGFR and STAT3 in the activation of iNOS/NO pathway. Cancer Cell 2005, 7(6):575-589.
35. Bigner S.H., Humphrey P.A., Wong A.J., Vogelstein B., Mark J., Friedman H.S., Bigner D.D. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990, 50(24):8017-8022.
36. Liao H.J., Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol. Biol. Cell 2007, 18(3):1064-1072.
37. Liao H.J., Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 2009, 69(15):6179-6183.
38. Kochi S.K., Collier R.J. DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp. Cell Res. 1993, 208(1):296-302.
39. He Y.Y., Huang J.L., Chignell C.F. Cleavage of epidermal growth factor receptor by caspase during apoptosis is independent of its internalization. Oncogene 2006, 25(10):1521-1531.
40. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7(3):683-694.
41. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001, 7(3):673-682.
42. Cao X., Rodarte C., Zhang L., Morgan C.D., Littlejohn J., Smythe W.R. Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol. Ther. 2007, 6(2):246-252.
43. Shao H., Cheng H.Y., Cook R.G., Tweardy D.J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003, 63(14):3923-3930.
44. Hung L.-Y., Tseng J.T., Lee Y.-C., Xia W., Wang Y.-N., Wu M.-L., Chuang Y.-H., Lai C.-H., Chang W.-C. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucl. Acids Res. 2008, 36(13):4337-4351.
45. Hanada N., Lo H.W., Day C.P., Pan Y., Nakajima Y., Hung M.C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinogen. 2006, 45(1):10-17.
46. Bandyopadhyay D., Mandal M., Adam L., Mendelsohn J., Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem. 1998, 273(3):1568-1573.
47. Wang S.C., Nakajima Y., Yu Y.L., Xia W., Chen C.T., Yang C.C., McIntush E.W., Li L.Y., Hawke D.H., Kobayashi R., Hung M.C. Tyrosine phosphorylation controls PCNA function through protein stability. Nat. Cell Biol. 2006, 8(12):1359-1368.
48. Lo H.W., Hsu S.C., Xia W., Cao X., Shih J.Y., Wei Y., Abbruzzese J.L., Hortobagyi G.N., Hung M.C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007, 67(19):9066-9076.
49. Lo H.W., Cao X., Zhu H., Ali-Osman F. COX-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol. Cancer Res. 2010, 8(2).
50. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., Hung M.C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13(5):385-393.
51. Okamura T., Singh S., Buolamwini J., Haystead T.A., Friedman H.S., Bigner D.D., Ali-Osman F. Tyrosine phosphorylation of the human glutathione S-transferase p1 by epidermal growth factor receptor. J. Biol. Chem. 2009, 284:16979-16989.
52. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11(3):577-590.
53. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3(9):802-808.
54. de la Iglesia N., Konopka G., Puram S.V., Chan J.A., Bachoo R.M., You M.J., Levy D.E., Depinho R.A., Bonni A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Devel. 2008, 22(4):449-462.
55. Okumura K., Zhao M., DePinho R.A., Furnari F.B., Cavenee W.K. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell cycle 2005, 4(4):540-542.